Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Progenics Pharmaceuticals (PGNX)

Progenics Pharmaceuticals (PGNX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 355,048
  • Shares Outstanding, K 86,597
  • Annual Sales, $ 34,990 K
  • Annual Income, $ -68,550 K
  • 60-Month Beta 1.89
  • Price/Sales 11.20
  • Price/Cash Flow N/A
  • Price/Book 11.60
Trade PGNX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.77
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/14/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.23
  • Growth Rate Est. (year over year) +434,447.83%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.72 +10.22%
on 05/20/20
4.83 -15.12%
on 06/08/20
+0.47 (+12.95%)
since 05/19/20
3-Month
2.05 +100.00%
on 03/20/20
4.83 -15.12%
on 06/08/20
+1.99 (+94.31%)
since 03/19/20
52-Week
1.89 +116.93%
on 03/19/20
6.37 -35.64%
on 12/23/19
-0.78 (-15.98%)
since 06/19/19

Most Recent Stories

More News
Lantheus Holdings Announces Presentations at the 33rd Annual European Association of Nuclear Medicine (EANM) Virtual Congress

Lantheus Holdings, Inc. (the "Company") (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc., and EXINI Diagnostics AB, and a global leader in the development,...

PGNX : 4.10 (-9.39%)
LNTH : 13.12 (-1.72%)
Lantheus Completes Merger with Progenics

Lantheus Holdings, Inc. (the "Company") (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. ("LMI"), a global leader in the development, manufacture and commercialization of innovative...

LNTH : 13.12 (-1.72%)
PGNX : 4.10 (-9.39%)
Independent Bank Group Set to Join S&P SmallCap 600

, /PRNewswire/ -- Independent Bank Group Inc. (NASD: IBTX) will replace Progenics Pharmaceuticals Inc. (NASD: PGNX) in the S&P SmallCap 600 effective prior to the opening of trading on . S&P Small-Cap...

IBTX : 48.86 (+0.91%)
PGNX : 4.10 (-9.39%)
LNTH : 13.12 (-1.72%)
SPGI : 346.89 (-0.37%)
Progenics Stockholders Approve Merger with Lantheus

Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) ("Progenics"), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, announced that at a special...

LNTH : 13.12 (-1.72%)
PGNX : 4.10 (-9.39%)
Lantheus Stockholders Approve Share Issuance For Merger with Progenics

Lantheus Holdings, Inc. (NASDAQ: LNTH) ("Lantheus" or the "Company"), parent company of Lantheus Medical Imaging, Inc. ("LMI"), a leader in the development, manufacture and commercialization of innovative...

LNTH : 13.12 (-1.72%)
PGNX : 4.10 (-9.39%)
Progenics Pharm Rises 2.56% on Heavy Volume: Watch For Potential Pullback

Progenics Pharm (NASDAQ:PGNX) traded in a range yesterday that spanned from a low of $4.25 to a high of $4.42. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high of...

PGNX : 4.10 (-9.39%)
SHAREHOLDER ALERT: WeissLaw LLP Investigates Progenics Pharmaceuticals, Inc.

, /PRNewswire/ --  is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company") (NASDAQ:...

PGNX : 4.10 (-9.39%)
LNTH : 13.12 (-1.72%)
Progenics to Present Results from the Phase 3 CONDOR Trial of PyL(TM) (18F-DCFPyL) in Prostate Cancer at the American Society of Clinical Oncology 2020 Virtual Scientific Program

- Met Primary Endpoint with a Correct Localization Rate of 84.8-87.0% -

PGNX : 4.10 (-9.39%)
Progenics Class Action: Halper Sadeh LLP Announces Filing Of Shareholder Class Action Lawsuit Against Progenics Pharmaceuticals, Inc.; Investors Are Encouraged To Contact The Firm

, /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces the filing of a shareholder class action lawsuit against Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) in connection...

LNTH : 13.12 (-1.72%)
PGNX : 4.10 (-9.39%)
Progenics: 1Q Earnings Snapshot

NEW YORK (AP) _ Progenics Pharmaceuticals Inc. (PGNX) on Thursday reported a loss of $16.8 million in its first quarter.

PGNX : 4.10 (-9.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics' first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic...

See More

Key Turning Points

2nd Resistance Point 5.13
1st Resistance Point 4.61
Last Price 4.10
1st Support Level 3.76
2nd Support Level 3.43

See More

52-Week High 6.37
Fibonacci 61.8% 4.66
Fibonacci 50% 4.13
Last Price 4.10
Fibonacci 38.2% 3.60
52-Week Low 1.89

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar